Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178442 | 0.81 | RARB (0.53) | CA12CA1CA2CA9RARB | |
| SCHEMBL798087 | 0.76 | KIF11 (0.50) | CA1CA2CA9 | |
| SCHEMBL9562875 | 0.75 | GRM5 (0.51) | CA12CA1CA2CA9RARB | |
| SCHEMBL12632231 | 0.73 | CA12 (0.53) | CA12CA1CA2CA9RARB | |
| SCHEMBL1086002 | 0.73 | RARB (0.62) | CA12CA1CA2CA9RARB | |
| SCHEMBL25413986 | 0.73 | RARB (0.65) | RARBRARG | |
| SCHEMBL1202204 | 0.72 | LOX (0.48) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL5441030 | 0.72 | PTGS2 (0.47) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL15472492 | 0.72 | PPARG (0.47) | CA1CA2CA9NR1H2 | |
| SCHEMBL1107981 | 0.71 | ALDH1A1 (0.64) | CA1CA2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |